JDRF celebrates today’s decision from the U.S. Food and Drug Administration (FDA) to approve teplizumab (under the brand name Tzield) for use in delaying type 1 diabetes (T1D) in at-risk individuals. This is a huge step on the path towards our vision of a world without T1D. Learn more about what this means for the #T1D community at the link in our bio! #NDAM #ForwardAs1